GSK’s chief commercial officer Luke Miels said the company is seeking to purchase or partner with biotechs "hiding in plain sight" as the drugmaker works to replenish its pipeline, the Financial Times’ Hannah Kuchler reports, citing the CCO. Miels said GSK is hoping to avoid "getting into a bidding war" by finding under-appreciated targets worth $1B-$2.5B, such as its takeover of Sierra Oncology earlier this year. Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GSK:
- Pfizer, Moderna among vaccine makers to watch in 2023, Barron’s says
- ProQR Therapeutics price target raised to $5 from $2 at Raymond James
- Sanofi, Pfizer settled first California Zantac bellwether case, says Barclays
- Biotech Alert: Searches spiking for these stocks today
- Vaxcyte initiated with a Buy at Guggenheim on pneumococcal vaccine potential